1. Viridian Therapeutics Plunges After Topline Phase 3 Data for Elegrobart in Thyroid Eye Disease
Viridian Therapeutics faces a severe market crisis as its lead drug candidate, elegrobart, delivered topline results from a late-stage clinical trial for thyroid eye disease (TED). The company's stock price plummeted immediately following the announcement, signaling a critical failure or underwhelming performance in a ...